A Study in People With Depression to Test the Effects of BI 1358894 on Parts of the Brain That Are Involved in Emotions
- Conditions
- Depressive Disorder, Major
- Interventions
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2025-02-25
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 73
- Registration Number
- NCT03854578
- Locations
- 🇩🇪
Charité - Universitätsmedizin Berlin, Berlin, Germany
A Study in Healthy Men Tests How Different Doses of BI 764198 Are Taken up in the Body and How Well They Are Tolerated.
- First Posted Date
- 2019-02-26
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 72
- Registration Number
- NCT03854552
- Locations
- 🇩🇪
CRS Clinical Research Services Mannheim GmbH, Mannheim, Germany
An Expanded Access Program to Provide Nintedanib to Patients With Non-IPF ILD Who Have no Alternative Treatment Possibilities
- Conditions
- Lung Diseases, Interstitial
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2024-12-10
- Lead Sponsor
- Boehringer Ingelheim
- Registration Number
- NCT03843892
- Locations
- 🇺🇸
Banner University Medical Center Tucson, Tucson, Arizona, United States
🇺🇸The Lung Research Center, LLC, Chesterfield, Missouri, United States
🇺🇸Glacier View Research Institute, Kalispell, Montana, United States
A Study to Test How Different Doses of BI 685509 Are Tolerated in Patients With Liver Problems
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2021-06-10
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 64
- Registration Number
- NCT03842761
- Locations
- 🇺🇸
American Research Corporation at the Texas Liver Institute, San Antonio, Texas, United States
A Study in Healthy Men to Test How Itraconazole Influences the Amount of BI 1358894 in the Blood
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2025-02-21
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 16
- Registration Number
- NCT03843151
- Locations
- 🇩🇪
CRS Clinical Research Services Berlin GmbH, Berlin, Germany
A Study to Test How Food Influences the Amount of BI 1291583 in the Blood of Healthy Men
- First Posted Date
- 2019-02-12
- Last Posted Date
- 2021-11-05
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 12
- Registration Number
- NCT03837964
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany
A Study to Test How Well Patients With Plaque Psoriasis Tolerate BI 730357 Over a Longer Period and How Effective it is
- First Posted Date
- 2019-02-08
- Last Posted Date
- 2022-11-18
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 165
- Registration Number
- NCT03835481
- Locations
- 🇺🇸
Total Skin and Beauty Dermatology Center, PC, Birmingham, Alabama, United States
🇺🇸Dermatology Research Associates, Los Angeles, California, United States
🇺🇸Southern California Dermatology Inc., Santa Ana, California, United States
A Study in Patients With Atopic Eczema to Test How Effective BI 655130 is and How Well it is Tolerated
- First Posted Date
- 2019-01-30
- Last Posted Date
- 2022-12-01
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 51
- Registration Number
- NCT03822832
- Locations
- 🇺🇸
Center for Dermatology and Plastic Surgery, Scottsdale, Arizona, United States
🇺🇸University of South Florida, Tampa, Florida, United States
🇺🇸ForCare Clinical Research, Inc., Tampa, Florida, United States
A Follow-up Study Investigating Long Term Treatment With Nintedanib in Patients With Progressive Fibrosing Interstitial Lung Disease (PF-ILD)
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2023-09-13
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 435
- Registration Number
- NCT03820726
- Locations
- 🇯🇵
National Hospital Organization Himeji Medical Center, Hyogo, Himeji, Japan
🇫🇷HOP Civil, Strasbourg, France
🇷🇺1stPavlov St.Med.Univ.St.-Petersburg Res.Inst., St. Petersburg, Russian Federation
A Study in Healthy People to Test if Taking Different Formulations of BI 425809 Tablets Influences the Amount of BI 425809 in the Blood
- Conditions
- Healthy
- Interventions
- Drug: BI 425809 (Treatment T1)Drug: BI 425809 (Treatment T2)Drug: BI 425809 (Treatment R)
- First Posted Date
- 2019-01-25
- Last Posted Date
- 2019-06-04
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 18
- Registration Number
- NCT03817476
- Locations
- 🇩🇪
Humanpharmakologisches Zentrum Biberach, Biberach, Germany